



RealRate

PHARMACEUTICAL 2020











RealRate

PHARMACEUTICAL 2020

NextCure Inc. Rank 41 of 362



The relative strengths and weaknesses of NextCure Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NextCure Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 189% points. The greatest weakness of NextCure Inc. is the variable Revenues, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 111%, being 414% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	339,995
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,042
Liabilities, Non-Current	3,333
Other Assets	4,083
Other Compr. Net Income	-38
Other Expenses	0
Other Liabilities	16,309
Other Net Income	3,745
Property and Equipment	12,090
Research and Development	34,216
Revenues	6,347
Selling, General and Administrative Expense	9,613

Output Variable	Value in 1000 USD
Assets	356,168
Liabilities	34,684
Expenses	43,829
Stockholders Equity	321,484
Net Income	-33,737
Comprehensive Net Income	-33,756
Economic Capital Ratio	111%

